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Abstract
Background: West Nile virus (WNV) is a neurotropic arbovirus that was first isolated in 1937 in the West Nile District
of Uganda. The virus emerged in New York in 1999 and is now endemic in North America (2007). The first virus
isolates from Puerto Rico were obtained in 2007 from a chicken (PR20wh) and a mosquito pool (PR423). Our study
further characterized these viral isolates using in vitro plaque morphology assays and in vivo using a Balb/c mice
pathogenesis model.
Methods and results: In the in vitro experiments, PR WNV isolates produced significantly smaller plaques in Vero cells
compared to the New York 1999 strain (NY99). For the in vivo experiments, PR WNV isolates were propagated in
mammalian (Vero) and insect (C6/36) cell lines and then inoculated in Balb/c mice. When WNV was propagated in Vero
cells, we observed a trend towards significance in the survival rate with PR20wh compared to NY99 (log rank, p = 0.092).
Regardless of whether the viral isolates were propagated in Vero or C6/36 cells, we found a significantly greater survival
in mice infected with PR20wh strain, when compared to NY99 (log rank, p = 0.04), while no statistical difference was
detected between PR423 and NY99 (p = 0.84). The average survival time (AST) in mice was significantly lower in
C6/36-derived PR423 when compared to C6/36-derived NY99 (t-test, p = 0.013), and Vero-derived PR423 (t-test, p < 0.001).
Eight days post infection in mice the viral load in brain tissue for Vero-derived PR423 was significantly higher when
compared to NY99 and PR20wh.
Conclusions: These results suggest that the PR WNV isolate, PR20wh, is a less pathogenic strain in mice than NY99.
Moreover, we found that PR423 is a pathogenic isolate that causes faster mortality than NY99, when propagated in C6/36.
Background
West Nile virus (WNV) is a neurotropic flavivirus which
emerged in 1999 in North America causing viral enceph-
alitis primarily in the elderly and immunocompromised
individuals [1]. WNV is now endemic in Africa, Asia,
Europe and more recently in North America [2–5]. Since
its emergence in North America, serological evidence in
horses and birds indicated that the virus was widely dis-
tributed throughout Mexico [6–9], the Caribbean [10–12],
Central America [13] and South America, specifically
Colombia, Venezuela, and Argentina [14–17]. Although
the evidence of WNV circulation in Brazil is limited to de-
tection of WNV-specific neutralizing antibodies in horses
[15, 18, 19], a human case of WNV encephalitis was
recently reported [20], suggesting the emergence of WNV
in this country.
WNV disease in humans has been rarely reported in
Latin America compared to reports from North America.
Additionally the high pathogenicity in American crows
(Corvus brachyrhynchos) and house sparrows (Passer
domesticus), exhibited by the original isolate from 1999
(NY99 strain) and the subsequently evolved strain from
2002 (WN02) has not been observed throughout the
Caribbean, Central and South America. A possible explan-
ation for these differences in pathogenesis between North
America and Latin America viral strains is the evolution
of less virulent strains in Latin America. Alternatively,
cross-protective immunity in humans due to the presence
of other flaviviruses in the Caribbean and Latin American
countries could partially explain the paucity in the number
of reported human cases with WNV disease in this region.
In Puerto Rico (PR), WNV was isolated in 2007 from
sentinel chicken serum (PR20wh) and Culex nigripalpus
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mosquito pool (PR423), representing the first isolates
from the Caribbean [12, 21]. Serological evidence in a
sentinel chicken surveillance indicated that the emer-
gence of WNV in PR occurred in June of 2007 [12]. Se-
quence analysis of the prM and E viral genes determined
one amino acid difference (V159A) between PR 2007
strains and NY99 [21]. This mutation was also observed
in the current dominant clade (WN02) circulating in the
United States, associated with increased viremia [22].
Interestingly, human disease was rarely detected following
the introduction of WNV in PR; only one symptomatic
WNV case was identified in an enhanced surveillance
study in 2007 [23].
In order to better understand the lack of both animal
and human WNV disease in PR following its introduction
in 2007, pathogenesis studies in mice were performed with
PR isolates (PR423 and PR20wh). Comparisons of mouse
survival rates, viremia levels and viral load in brain
tissue between NY99 and PR isolates (PR423 and
PR20wh) were evaluated. The results of our study
showed that PR20wh was less pathogenic in mice than
NY99 while PR423 caused similar pathogenicity with
faster mortality than NY99.
Results
Plaque morphology and growth curve analysis
Vero cells were infected for 3 and 4 days with WNV
NY99, PR20wh and PR423, and plaque size was mea-
sured. PR isolates showed smaller plaques when com-
pared to its parental strain NY99 (Fig. 1). In addition,
only a slight difference in plaque size from day 3 to day
4 was observed in the PR20wh isolate. ANOVA analysis
indicated significant differences in plaque size between
NY99 and PR isolates (p = 0.002 (day 3), p = 0.0001
(day 4)).
Pathogenesis of WNV strains in mice
Mice were inoculated by intraperitoneal (IP) injection
with 105 plaque forming units (pfu). This is the median
viral dose of inoculum recommended in vivo to achieve
a similar dose as inoculated by Culex mosquito species
from a natural infection [24]. Most infected mice
presented clinical signs of WNV disease such as, weight
loss, ruffling coat, hunchback posture, and hind leg
paralysis by 6 days post infection (dpi). For mice inocu-
lated with the Vero cell–derived viruses from NY99,
PR423 and PR20wh, we observed a morbidity of 90, 80
and 80 %, respectively. Similar morbidity and convales-
cence results were observed in mice inoculated with C6/
36 derived WNV when compared with the Vero derived
viruses. Mortality in mice inoculated with the Vero de-
rived NY99 and PR20wh was observed starting on 7 dpi,
followed by the PR423 group on 8 dpi. The mice survival
rate from the Vero derived WNV strains were 30 % for
NY99, 40 % for PR423 and 70 % for PR20wh (Fig. 2a). A
trend towards a higher survival rate in PR20wh-
inoculated mice was observed when compared to the
control group, NY99 (p = 0.092). However, no significant
differences in survival were observed between PR423
and NY99. Mortality of mice inoculated with the C6/36
derived PR423 isolate began on 5 dpi, followed by the
other two groups (NY99 and PR20wh) on 7 dpi. Survival
rate in mice of the C6/36-derived WNV was 20 % for
NY99, 30 % for PR423 and 50 % PR20wh (Fig. 2b).
Statistical analysis determined no significant differences
in survival rates between the three viruses (NY99, PR423
and PR20wh) derived from C6/36 cells.
The comparison of the survival rate was performed for
each WNV strain depending on the cell type used for
virus propagation (Vero vs. C6/36). Survival rate for all
groups infected with C6/36-derived virus decreased by
at least 10 %, in comparison with the groups inoculated
Fig. 1 Plaque size for PR isolates compared to its parental strain, NY99. Vero cells were infected for either 3 or 4 days with the WNV and plaque sizes
were measured expressed as least square means (LS Means) in inches. ANOVA analysis indicated that the PR isolates had statistically significantly
smaller plaques than NY99. (*p = 0.002, **p = 0.0001)
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with Vero-derived WNV. However, the differences in
survival rate by viral source were not statistically signifi-
cant. Therefore, we combined the results from the two
experiments and compared the survival rate of the 3 vi-
ruses regardless of the viral source. The overall survival
rate after WNV inoculation was 25 % for NY99, 35 %
for PR423 and 60 % for PR20wh (Fig. 3). The survival
rate for the mice inoculated with PR20wh isolate was
significantly higher (p = 0.04) when compared to NY99.
These results suggest that PR20wh displayed an attenu-
ated phenotype in 9-week-old BALB/c mice at the
inoculum of 105 pfu.
Average survival time after WNV inoculation
Table 1 shows the average survival time (AST) calculated
following inoculation with WNV isolates. A higher mor-
tality rate was observed in mice when inoculated with the
PR423, derived either from Vero cells (AST = 8.66 ± 0.81)
or from C6/36 cells (AST = 6.14 ± 1.34). However PR423
isolate didn’t cause higher mortality compared to NY99.
Statistical analysis showed significantly lower AST in
PR423-inoculated mice than in NY99-inoculated mice,
when both viruses were C6/36-derived (t-test, p = 0.013).
Comparison of the AST of PR423 propagated in C6/36 vs.
Vero cells, also revealed a significant difference (t-test,
p = <0.001). These results suggested that C6/36-derived
PR423 caused faster mortality than C6/36-derived
NY99 and Vero-derived PR423.
Comparison of WNV PR and NY99 Viremia in Mice
Low levels of viremia (>10 pfu/ml) were observed for all
Vero-derived WNV strains with the peak viremia
detected on 4 days post inoculation (dpi) (Fig. 4a). No
statistical differences in viremia levels were noted among
A
B
Fig. 2 Survival after WNV inoculation. Nine week old Balb/c mice were IP inoculated with 105 pfu of each WNV isolate, collected from either Vero
(a) or C6/36 (b) cells. For each group, 10 mice were observed for morbidity and mortality for 28 days and the other 20 mice were sacrificed on
days 2, 4, 6, 8, and 10 post-infection (4mice/day). Log rank test was performed to determine differences in survival rate between the PR isolates
and the parental strain, NY99. When strains were Vero-derived, a trend towards a higher survival was observed in mice inoculated PR20wh when
compared to NY99 (*p = 0.092). No significant differences in survival were observed, when mice were inoculated with C6/36-derived viruses. Only
one experiment was performed
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these three viruses. For C6/36-derived viruses, the peak
viremia was detected on 2 dpi (Fig. 4b). When compar-
ing the peak viremia of the PR isolates to NY99, we
found a significantly higher viral titer in mice inoculated
with PR423, when the virus was propagated in C6/36
cells (p ≥ .001). Moreover, significant differences were
observed on viremia levels for **Vero-derived PR423 on
2dpi by cell type (**p ≥ .0001; PR423-Vero vs. PR423-C6/
36). These results suggest that PR423 was associated
with high viremia levels when the virus was propagated
in C6/36 cells.
Comparison of WNV PR and NY99 Viral load in mouse
brain
The viral titer in brain specimens peaked on 8dpi only
for PR423-inoculated group (Fig. 5). Viral titer for Vero-
derived PR423 was significantly higher compared to
NY99 and PR20wh on 8 dpi (Fig. 5a). C6/36-derived
PR423 inoculated mice displayed higher but not signifi-
cantly different levels of viral titer on 8 dpi, when com-
pared to NY99 and PR20wh (Fig. 5b) [18]. The PR20wh
isolate caused the lowest viral titer in brain specimens
when derived from Vero cells (Fig. 5a). However, this
isolate exhibited an overall higher viral titer in brain
specimens when grown in C6/36 cells, although this dif-
ference was not statistically significant (Fig. 5b). Viral ti-
ters in brain specimens for PR20wh corresponded with
the higher survival rate, since the lowest viral titer and
highest survival rate was observed when the virus was
Vero-derived. Moreover, C6/36-derived PR20wh caused
an increase in viral titer and a decrease in survival rate.
Discussion
The main objective of our study was to characterize the
PR WNV isolates in mice and determine if pathogenesis
was dependent on virus propagated in mosquito or mam-
malian cells. Previous studies suggested that infection with
WNV strains passaged in mosquito cells (C6/36) would
cause higher mortality in mice than those passaged in
Vero cells [25–28]. Plaque morphology comparisons
between the PR isolates and NY99 indicated that PR iso-
lates produced significantly smaller plaques suggestive of a
less pathogenic virus [29, 30]. However after day 4 of
infection, the plaque size suggested that the two PR iso-
lates were different since plaque size continued to increase
in PR423 infected cells over time but little or no change
was observed in plaque size from PR20wh isolate.
The cell source (mammalian vs insect) used for virus
propagation plays an important role in the initial virus–host
interactions. Several in vitro studies with WNV and alpha-
viruses demonstrated a preferential binding of mosquito
cell-derived viruses to the dendritic cell-intracellular
adhesion molecule (ICAM)-3 grabbing non integrin related
(DC-SIGNR) and an enhanced infection of dendritic cells
with mosquito cell-derived viruses compared to viruses
propagated in mammalian cells [25–28]. Although in vitro
studies demonstrated the importance of cell source in the
pathogenesis of WNV, limited information is available in
Table 1 Average survival time following inoculation with WNV
WNV Strains Vero derived C6/36 derived
AST ± SD AST ± SD
NY99 9.14 ± 2.47 8 ± 1.06*
PR423 8.66 ± 0.81** 6.14 ± 1.34*
PR20wh 9.33 ± 4.04 7.6 ± 0.54
This table shows the average survival time (AST) ± standard deviation of Balb/c
mice after inoculation with the WNV NY99, PR423 and PR20wh. The student
t-test analysis showed a significantly lower AST in the C6/36-derived PR423
group when compared to C6/36-derived NY99 (p = 0.013*) and Vero-derived
PR423 strains (p < 0.001**)
AST average survival time, SD standard deviation, PR423 and PR20wh, Puerto
Rico WNV isolatesWNV =West Nile virus
Student t test: PR423 (C6/36) VS:PR423 (Vero)** = p < 0.001,
Student t test: PR423 (C6/36) VS:NY99 (C6/36)* = p = 0.013
Fig. 3 Overall survival after WNV inoculation. Survival experiments from Vero and C6/36 cell derived WNV were pooled. Log rank test demonstrated
that PR20wh caused higher survival in mice than NY99 (*p = 0.04)
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vivo [25]. Lim et al., examined WNV pathogenesis in mice
when virus was derived from mosquito versus mammalian
cells and concluded that cell source caused a minimal effect
in the mortality of the infected mice at low viral doses (1
and 10 pfu) [31]. Our results were consistent with Lim et
al., findings as no significant differences in survival were
observed when NY99 and the PR isolates when derived
from either mosquito or mammalian cells. When the re-
sults from both in vivo experiments were combined for
analysis, the overall survival rate was significantly higher
in mice inoculated with PR20wh in comparison to those
inoculated with NY99. These data, in addition to the ob-
served small plaque morphology for PR20wh, suggested
that this isolate is less pathogenic in mice than NY99.
Similar results were obtained in studies from other Latin
America WNV isolates [14, 32, 33]. Indeed, WNV isolate
from Tabasco, Mexico (TM171-03) when challenged in
American crows, house sparrows and a murine model
was shown to be attenuated [9, 29, 32]. Likewise, a
variant of the WN02 strain isolated in Houston, Texas
(BIRD1153) also showed reduced neuroinvasiveness in
mice [30, 32, 34]. Higher survival rates and small plaque
morphology are characteristics of the Mexican attenuated
WNV variant TM171-03, similar to the findings observed
with PR isolate, PR20wh [9, 29, 30, 32].
In the in vivo experiments, the peak viremia was sig-
nificantly higher for PR423 in comparison to NY99
when the virus was propagated in C6/36 cells. This was
not surprising since PR423 has the same V159A
mutation as the WNV02 dominant clade which corre-
lates with higher viremia [12, 35]. Most pathogenesis
studies have shown that WNV-induced mortality in
mice correlates with WNV neuroinvasion [36]. In
accordance to this observation, the peak viral titer ob-
served in brain specimens was detected earlier (8 dpi)
in the PR423 infected groups while viral titers contin-
ued to increase up to 10dpi in the NY99 and PR20wh
infected groups. This may explain the AST results
suggesting that PR423 causes faster mortality in mice
than NY99. We also observed a direct relationship
between virus titers in brain specimens and mortality
in the PR20wh-inoculated groups. When PR20wh was
Fig. 4 Viremia levels after WNV inoculation. Viremia levels of mice inoculated with Vero–derived (a) and C6/36-derived (b) strains. An ANOVA analysis
showed significantly higher peak viremia in mice inoculated with C6/36-derived PR423 isolate when compared to the other groups (*p < 0.001 PR423
vs. NY99). Viremia levels of PR423 on day 2 were also significantly different when compared according to the cell source (**p < 0.0001 PR423-Vero vs.
PR423-C6/36 on day 2)
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propagated in Vero cells, the lowest viral titer in
brain specimens was observed along with higher sur-
vival. The result from our study was consistent with
the attenuated Mexican variant (TM171-03 pp1) where
reduced neuroinvasion in a murine model was observed
[12, 29, 35].
Our findings showed that WNV isolates from PR ex-
hibited two different phenotypes, PR20wh exhibited a
less pathogenic phenotype than NY99 while PR423 had
similar pathogenicity to its parental strain. In Colombia
a similar situation was observed where a pathogenic
phenotype which exhibited high virulence in Balb/c mice
was observed from two WNV isolates from Colombia
(COL 524/08, 9835/08) originally obtained from healthy
captive American Flamingoes (Phoenicopterus ruber)
[37]. However, two strains recently isolated from mos-
quito pools in Colombia were reported to be closely
related to attenuated strains from Texas [38]. Although
phenotypic characterization of these new Colombian
strains has not yet been perform to confirm attenuation,
Lopez et al., findings demonstrated the circulation in
Colombia of genetic diverse WNV strains [38]. Thus, it
is possible that WNV strains isolated from both the
Caribbean and Latin America have variable pathogenic
capacities.
A large sample size of North America isolates have been
collected and sequenced since the introduction of WNV
in 1999, due to improved surveillance and the high patho-
genicity of these strains in horses and bird species [32].
Such high pathogenicity has not been observed in Latin
American and the Caribbean WNV strains [32]. Moreover,
there is paucity in the number of reported human cases
with WNV disease in Latin America and the Caribbean
[39]. Indeed, only one symptomatic case of WNV disease
was identified in PR during an enhanced human surveil-
lance study on 2007 [23] and recently a human case of
WNV encephalitis was reported in Brazil (Vieira et al.,
[20]). Possible explanations for the differences in WNV
disease observed in humans, horses and birds between
North America compared virus strains and Latin America
include: 1. The circulation of attenuated strains in Latin
America and the Caribbean, 2. the natural resistance to
Fig. 5 Viral Load after WNV inoculation. Viral load of mice inoculated with Vero–derived WNV (a) and C6/36-derived WNV (b) isolates. One-way
ANOVA analysis showed that viral load for Vero-derived PR423 isolate on 8dpi was significantly higher when compared to NY99 and PR20wh
(*p < 0.001 PR423 vs. NY99 and **p = 0.0001 PR423 vs. PR20wh)
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WNV infection in birds in Latin America [40] 3. an in-
creased avian diversity in the tropics [41] 4. the co-
circulation of other flaviviruses such as dengue virus that
may confer some cross-protective immunity in humans
and 5. the limited viral isolates obtained due to non-
sustainable WNV surveillance in humans and animals in
Latin America [42]. Additional studies are needed to bet-
ter understand the genotypes and their corresponding
phenotypes of WNV strains circulating in PR and Latin
America.
Conclusions
PR423 and PR20wh are the first WNV isolates from the
Caribbean. PR20wh was less pathogenic than NY99
whereas PR423 had similar pathogenesis as its parental
strain. Further characterization at the molecular level is
necessary to understand the difference in pathogenicity
of these two WNV viral strains.
Methods
Virus strains
WNV isolates were obtained from the reference collection
from the Centers for Disease Control and Prevention,
Division of Vector-Borne Diseases, Dengue Branch, San
Juan, Puerto Rico (CDC DVBD-DB). The NY99 strain was
isolated from an infected Chilean flamingo in the Bronx
Zoo and was passaged once in suckling mice and twice in
Vero cells [43]. In this study, NY99 was used at passage 4.
The Puerto Rico isolates, PR423 and PR20wh, were iso-
lated from mosquito pools (Culex nigripalpus) and serum
from a sentinel chicken, respectively. These viral strains
were passaged twice in Vero (ATCC) cells prior to this
study [12]. In this study the PR strains were used at
passage 3.
Virus infection
C6/36 (Aedes albopictus cell line ATCC® CRL-1660) and
Vero (African green monkey kidney cells) were infected
with WNV (NY99, PR423, and PR20wh) at a multiplicity
of infection (MOI) of 0.1 as previously described [43].
Briefly, C6/36 and Vero cells monolayers were infected
and incubated for one hour at room temperature. C6/36
cells were maintained in DMEM supplemented with
10 % Fetal Bovine Serum (FBS) and incubated at 33 °C
for 3 days without CO2. Vero cells were maintained in
M-199 supplemented with 10 % FBS and incubated at
37 °C for 3 days. Viral stocks were collected for virus
titration. The envelope protein glycosylation pattern of
the PR isolates and NY99 was verified by western blood
analysis.
Virus plaque titration assay
Vero cells were seeded in Costar 12-well cell culture plates
(Corning Incorporated, Corning, NY) and incubated for
24 h (hrs) at 37 °C in 10 % CO2. The cell monolayers were
inoculated with 10-fold serial dilutions of each viral strain;
in a final volume of 0.1 milliliter (ml). Viral adsorption
was performed for 1 h at 37 °C with rocking of the plates
every 15 min. A 2-ml overlay of MEM, 5 % FBS, and 0.6 %
agarose was added after incubation as described by Eckels
et al. [44]. The infected monolayers were incubated at
37 °C in 5 % CO2. After 2–3 days of infection, a second
overlay containing 1.5 % neutral red (Sigma–Aldrich
Co., St. Louis, MO), was added to each well, and the
plates were incubated at 37 °C in 5 % CO2 overnight.
The following day the plaques were counted and the
viral titer was expressed as pfu/ml.
Plaque size analysis
Vero cells were seeded into 6-well plates and infected with
the PR isolates and NY99 (all viral stocks were previously
propagated in Vero cells) for 1 h. A 2-ml overlay of MEM,
5 % FBS, and 1 % SeaKem ME AGAROSE (Lonza
Rockland, ME) was added following virus adsorption as
previously described by Eckels et al. [44]. After staining
with neutral red, plaques were counted at the indicated
times post-infection. Plaque size analysis was assessed
using calipers to measure twenty plaques in two separate
wells on day 3 or 4 days post-infection (dpi).
Animal studies
Nine week old Balb/c mice were purchased from Charles
River Laboratories (Boston, MA), and were intraperito-
neally (IP) inoculated with each WNV strain collected
from either mosquito (C6/36) or mammalian cells
(Vero) as previously described by Ben-Nathan et al.,
[45]. Mice were divided in groups of 30, of which 10
mice were observed for morbidity and mortality for
28 days and the other 20 mice were sacrificed on days 2,
4, 6, 8, and 10 post-challenge for viral load determina-
tions. Symptoms of WNV encephalitis such as weight
loss, ruffling, hunchback posture and hind-leg paralysis
were recorded. Blood specimens were obtained by retro-
orbital method on the day of WNV inoculation and
intracardially from sacrificed mice [46]. The brain was
removed from sacrificed animals. The average survival
time (AST) (the average time in days needed to cause
death of mice) excluding survivors, was determined. Real
time RT-PCR was performed on serum and brain speci-
mens to measure viremia and viral load, respectively.
Mice that survived the WNV infection were sacrificed at
the end of the experiment (28 days post-infection), and
intra-cardiac and brain samples were obtained. Animal
procedures were performed in compliance with the
University of Puerto Rico Medical Sciences Campus
Institution Animal Care and Use Committee (IACUC),
approved protocol 2460408.
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Viral RNA isolation
Viremia and viral load was determined by real-time
quantitative RT-PCR from serum samples and brain
specimens collected on 0, 2, 4, 6, 8 and 10 days post
WNV infection. The QIAmp viral RNA kit (QIAgen,
Valencia, CA) was used for viral RNA isolation from
serum samples and from virus stocks (for the standard
curve). Briefly, 560 μl of the Buffer AVL were added to
100 μl of the serum or virus stock and mixed. Following
10 min incubation at room temperature, 560 μl of
ethanol (96–100 %) was added. Next, 630 μl of the sam-
ple was applied to the QIAamp Mini spin column and
centrifuged at 8000 rpm for 1 min. Then 500 μl of Buffer
AW1 was added to the column and centrifuged for
1 min at 8000 rpm, followed by 500 μl of Buffer AW2
and a second centrifugation for 3 min at 14,000 rpm.
The column was placed in a clean 1.5 micro centrifuge
tube and 60 μl of Buffer AVE was added and incubated
for 1 min at room temperature. Elution of the RNA was
completed following a centrifugation for 1 min at
8000 rpm. Viral RNA samples were stored at −70 °C
until use.
Viral RNA extraction from the brain tissue was per-
formed using the QIAgen RNeasy Lipid Tissue Midi Kit.
The brain tissue was harvested in RNAlater RNA
Stabilization Reagent (QIAgen, Valencia, CA) and stored
at −80 °C until processing. Briefly, 300 to 310 mg of
brain tissue was homogenized in 5 mL of QIAzol re-
agent (QIAgen, Valencia, CA) using 2 ml tissue grinders
(Wheaton, Millville, NJ). After homogenization, samples
were transferred into 15 ml polypropylene tubes and
mixed with 1 mL of chloroform. After 3 min incubation
at room temperature, samples were centrifuged for
20 min at 3000 rpm at 4 °C. Then, the upper aqueous
phase was transferred to a new polypropylene tube, and
3 ml of 70 % ethanol were added. Samples (4 mL) were
transferred to a column centrifuged for 5 min at
3000 rpm at room temperature and the flow-through
was discarded. This procedure was repeated with the
remaining sample. The sample was washed once with
4 ml of buffer RW1, (2 min centrifugation at 3000 rpm)
and twice with 2.5 ml Buffer RPE. A 5 min centrifugation
at 3000 rpm was performed and the column was trans-
ferred into a new 15 ml tube. Elution was performed with
150ul RNase-free water. After 2 min incubation at room
temperature, the sample was centrifuged for 3 min at
3000 rpm, for elution. The viral RNA samples were stored
at −70 °C until use.
Real time RT-PCR
TaqMan assays were performed to determine WNV viral
load as previously described by Lanciotti and collabora-
tors [47]. Briefly, a master mix consisting of 5 μl of viral
RNA (vRNA) extracted from serum or brain samples,
50pmol of each primer and 10pmol of the FAM labeled
probe was prepared and adjusted to a total of 50uL. The
iScript One-Step RT-PCR kit for Probes (Bio-Rad
Hercules, CA) was used. Serial dilutions of the viral
RNA extracted from WNV-NY99 stocks were made to
construct the standard curve and determine the pfu/ml
or pfu/ mg based on cycle threshold values (Ct). Ampli-
fication protocol was performed as follows: 1 RT cycle of
50 °C for 30 min, 1denaturation cycle at 95 °C for
10 min, 45 annealing cycles at 95 °C for 15 s and 60 °C
for 1 min and 1 extension cycle of 68 °C for 3 min using
an iQ4 Multicolor Real-Time PCR Detection System
(Bio-Rad, Hercules, CA).
Statistical analysis
Survival analysis was performed by the Kaplan-Meier
method using log-rank test to compare survival rates
among groups. Average survival time (AST), was calcu-
lated for every group of inoculated mice and compared
using student t test. Viral loads were log transformed for
statistical tests. Mean log viral load was analyzed by one
way ANOVA and the geometric mean titers were ana-
lyzed by one-way ANOVA and the Bonferroni adjust-
ment was applied for multiple comparisons. All analysis
was performed using Graphpad® Prism statistical pro-
gram, Version 5 (La Joya, CA).
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